Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-Label Extension Study of Belcesiran in PiZZ Alpha-1 Antitrypsin Deficiency–Associated Liver Disease
2021-005217-14Phase 2Terminated
- Sponsor
- Dicerna Pharmaceuticals, Inc.
- Start
- Mar 2022
- Modality
- Gene Therapies, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of belcesiran in alpha-1 antitrypsin deficiency-associated liver disease, sponsored by Dicerna Pharmaceuticals, Inc. Primary endpoint: Treatment-emergent adverse events and safety parameters. Started Mar 2022; status: terminated.
02
Drugs
belcesiran
03
Conditions
alpha-1 antitrypsin deficiency-associated liver disease
Beyond the preview
Go deeper on 2021-005217-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005217-14.